The Scale Doesn't Show What's Actually Leaving: Muscle Loss on a Working GLP-1
A 71-year-old woman losing weight steadily on semaglutide is also losing a meaningful share of it as muscle, not fat — a real, underexplained cost of rapid GLP-1-driven weight loss in an older patient who cannot afford to lose strength.
Yvonne T., a 71-year-old retired church organist, still plays for two services most Sundays, though she mentioned this visit, almost as an aside, that she's had to ask her son to carry the hymnals up from the choir room lately because the stairs and the weight of the boxes together have started to feel like more than she wants to manage alone. She started semaglutide eight months ago for obesity-related osteoarthritis and hypertension, and the results by the numbers alone look like an unambiguous success: a BMI down from 34 to 29, blood pressure improved, her orthopedist pleased with reduced knee loading.
What the numbers alone don't show is what her grip-strength testing at today's visit found: a measurable decline from her baseline six months ago, out of proportion to what her age alone would predict over that interval. The DEXA body-composition substudies of STEP 1 and SURMOUNT-1 have found that a meaningful share of total weight lost on these drugs — commonly cited at roughly a quarter to as much as 40% in some analyses — is lean tissue rather than fat, a cost that matters little in a 35-year-old with muscle reserve to spare and matters a great deal in a 71-year-old whose functional independence already depends on the strength she has left.
Yvonne's own read on the hymnal-box story was matter-of-fact rather than alarmed, which is part of what makes this visit worth taking seriously before it becomes something she notices on her own in a more consequential way — on a flight of stairs, or getting up from a low chair, rather than carrying boxes she can simply choose to ask for help with.
In follow-up, a number that hid what was actually leaving
I want to slow the dose escalation and add resistance training before we push her any higher. Body-composition substudies from the STEP and SURMOUNT programs have found that a meaningful fraction of total weight lost on GLP-1 therapy — commonly cited in the range of a quarter to as much as 40% in some analyses — is lean mass, not fat, and she's 71, with grip strength that has measurably fallen from her own six-month baseline. Losing muscle at this rate isn't a cosmetic side effect for her; it's a direct pathway to frailty.
Agreed on the concern, and I'd add the mechanism: rapid, calorie-restriction-driven weight loss of any kind, pharmacologic or otherwise, disproportionately draws on lean tissue when protein intake and mechanical loading aren't actively preserving it — this isn't a GLP-1-specific toxicity, it's what aggressive weight loss does generally when nothing pushes back against it. Investigational combinations pairing a GLP-1 or GIP agonist with a muscle-preserving agent like bimagrumab, an activin receptor antagonist, have shown reduced fat loss coupled with better-preserved lean mass in early trials, though that combination isn't an approved option we can prescribe her today.
What we can control today is protein intake and resistance training, which have already been shown to blunt lean-mass loss during GLP-1 therapy in the populations that have been studied for it.
Then here's the concrete plan: hold her at the current dose rather than escalate further for now, target at least 1.0 to 1.2 grams of protein per kilogram of body weight daily, and get her into twice-weekly resistance training before we revisit the dose question. I'd rather she lose weight more slowly and keep her strength than chase a faster number on the scale that costs her the muscle she needs to stay independent.
Agreed: hold her semaglutide dose rather than escalate, set a protein target of 1.0 to 1.2 g/kg/day, and begin twice-weekly supervised resistance training, with grip strength and functional testing rechecked at the next visit before any dose decision is revisited.
No real disagreement remained; the plan was presented to Yvonne as a genuine adjustment to her goals, not a step backward, and she was told plainly that a slower path to her target weight that preserved her strength was worth more to her actual independence than a faster one that didn't.